

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Combination immune checkpoint blockade with ipilimumab/nivolumab is _____ to anti-PD-1 monotherapy for patients with melanoma and brain metastases.
 - a. Equivalent
 - b. Inferior
 - c. Superior
2. Results of the Phase III COLUMBUS trial evaluating encorafenib/binimetinib versus vemurafenib or encorafenib for unresectable or metastatic melanoma with a BRAF V600 mutation demonstrated significant improvement in _____ with encorafenib/binimetinib compared to vemurafenib.
 - a. Overall survival
 - b. Progression-free survival
 - c. Both a and b
 - d. Neither a nor b
3. Patients with melanoma who receive encorafenib/binimetinib are significantly more likely than those who receive dabrafenib/trametinib or vemurafenib/cobimetinib to experience treatment-associated fevers or photosensitivity.
 - a. True
 - b. False
4. The target of the monoclonal antibody tremelimumab is _____.
 - a. PD-1
 - b. CTLA-4
 - c. LAG-3
5. For patients with melanoma receiving combination immune checkpoint blockade who experience hypophysitis-associated headache, the side effect typically _____.
 - a. Resolves rapidly upon administration of steroids
 - b. Occurs throughout the course of therapy regardless of preventive measures
6. Data published by Migden and colleagues in the *The New England Journal of Medicine* evaluating PD-1 blockade with cemiplimab for locally advanced or metastatic SCC of the skin demonstrated durable responses and a tolerable side-effect profile and led to its recent FDA approval in this setting.
 - a. True
 - b. False
7. When used in the treatment of BCC, the hedgehog inhibitor sonidegib _____.
 - a. Can cause muscle spasms, hair loss and changes in taste
 - b. Can elicit responses after reinitiation of therapy following a treatment holiday to mitigate toxicities
 - c. Both a and b
 - d. Neither a nor b
8. Results of the Phase II JAVELIN Merkel 200 trial demonstrated durable responses and promising survival outcomes in patients who received the anti-PD-L1 antibody avelumab for metastatic Merkel cell carcinoma after disease progression on chemotherapy.
 - a. True
 - b. False
9. Which of the following categories reflects the mechanism of action of epacadostat?
 - a. Anti-PD-1/PD-L1 antibody
 - b. Anti-CTLA-4 antibody
 - c. Hedgehog inhibitor
 - d. IDO inhibitor
10. SCC of the skin is typically associated with long-term unprotected sun exposure, and metastasis to distant sites occurs only in a small proportion of patients.
 - a. True
 - b. False